REGENXBIO, Inc. is a company in the U.S. stock market and it is a holding in 54 U.S.-traded ETFs. RGNX has around 6.3M shares in the U.S. ETF market. The largest ETF holder of RGNX is the iShares Core S&P Small-Cap ETF (IJR), with approximately 1.85M shares. Investors may also find of interest that the ETF with the largest allocation to RGNX stock is Global X Genomics & Biotechnology ETF (GNOM), with a portfolio weight of 1.53%. On average, U.S. ETFs allocate 0.16% of RGNX to their portfolios.
Additionally, RGNX is a favorite stock for Vanilla and Growth ETFs. It is also most likely to belong to Broad-based ETFs. The best-performing ETF in the past 12 months with RGNX as a holding is the Virtus LifeSci Biotech Clinical Trials ETF (BBC), with a return of 48.68%.